Ramezani Neda, Ashtari Fereshteh, Bastami Elahe Abdi, Ghaderi Kimia, Hosseini Sayed Mohsen, Naeini Maryam Kazemi, Rajabi Fatemeh, Adibi Iman
Isfahan Neurosciences Research Center, Isfahan University of medical sciences, Isfahan, Iran.
Isfahan Neurosciences Research Center, Isfahan University of medical sciences, Isfahan, Iran; Department of neurology, School of medicine, Isfahan University of medical sciences, Isfahan, Iran.
Mult Scler Relat Disord. 2021 May;50:102798. doi: 10.1016/j.msard.2021.102798. Epub 2021 Jan 29.
There are reports that stress-related disorders are increasing during coronavirus disease 2019 (COVID-19) pandemic. Patients with Multiple Sclerosis (MS) are at higher risk of developing psychiatric disorders, which result in worsening of their disability. There are concerns about the mental health of MS patients during this pandemic.
We aimed to evaluate the prevalence of anxiety, depression, and levels of fear about Corona in MS patients during the COVID-19 pandemic.
This was a cross-sectional study on MS patients who were admitted to the MS clinics affiliated with Isfahan University of medical sciences from May to June 2020. Anxiety and depression were evaluated according to the Hospital Anxiety and Depression Scale (HADS). The Corona Fear Questionnaire developed by Ahorsu et al. was applied to evaluate the state of fear about COVID-19. Chi-square tests were used to compare depression and anxiety between different groups, Kruskal-Wallis was used for fear scores, Spearman correlation coefficient was also reported for correlations.
410 MS patients with a mean age of 38.6 years (±10.35) were enrolled in the study. Among those patients who answered the HADS questionnaire completely (n=399, n=388, for anxiety and depression subscales respectively) the prevalence of anxiety and depression were 31.2% (n=128) and 39.3% (n=161), respectively. There was no significant relationship between anxiety and depression with any of the following variables: sex, marital status, history of drug abuse, smoking, duration of taking psychiatric medication, being tested for COVID-19, being quarantined. Regarding fear about COVID-19, patients with depression or anxiety showed higher scores on the fear questionnaire (p-value=0.03, p-value=0.008 respectively).
The prevalence of anxiety and depression in MS patients was higher than previously reported. Fear about COVID-19 was correlated with anxiety and depression. Multicenter studies are required to develop specific recommendations for screening mental health problems in MS patients during COVID pandemic.
有报告称，在2019冠状病毒病（COVID-19）大流行期间，与压力相关的疾病正在增加。多发性硬化症（MS）患者患精神疾病的风险更高，这会导致他们的残疾状况恶化。在这次大流行期间，人们对MS患者的心理健康感到担忧。
我们旨在评估COVID-19大流行期间MS患者焦虑、抑郁的患病率以及对新冠病毒的恐惧程度。
这是一项对2020年5月至6月在伊斯法罕医科大学附属MS诊所就诊的MS患者进行的横断面研究。根据医院焦虑抑郁量表（HADS）评估焦虑和抑郁情况。采用Ahorsu等人编制的新冠恐惧问卷来评估对COVID-19的恐惧状态。使用卡方检验比较不同组之间的抑郁和焦虑情况，使用Kruskal-Wallis检验分析恐惧得分，还报告了Spearman相关系数以分析相关性。
410名平均年龄为38.6岁（±10.35）的MS患者参与了该研究。在完全回答了HADS问卷的患者中（焦虑和抑郁分量表分别为n = 399和n = 388），焦虑和抑郁的患病率分别为31.2%（n = 128）和39.3%（n = 161）。焦虑和抑郁与以下任何变量之间均无显著关系：性别、婚姻状况、药物滥用史、吸烟、服用精神科药物的时长、是否接受过COVID-19检测、是否被隔离。关于对COVID-19的恐惧，抑郁或焦虑患者在恐惧问卷上的得分更高（p值分别为0.03和0.008）。
MS患者中焦虑和抑郁的患病率高于先前报告。对COVID-19的恐惧与焦虑和抑郁相关。需要开展多中心研究，以制定在COVID大流行期间筛查MS患者心理健康问题的具体建议。
